...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biomaterials >Site-specific MOF-based immunotherapeutic nanoplatforms via synergistic tumor cells-targeted treatment and dendritic cells-targeted immunomodulation
【24h】

Site-specific MOF-based immunotherapeutic nanoplatforms via synergistic tumor cells-targeted treatment and dendritic cells-targeted immunomodulation

机译：基于特异性MOF基免疫治疗纳米型通过协同肿瘤细胞靶向治疗和树突细胞靶向免疫调节

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

An efficient antitumor immune response relies on multiple cells-based process including tumor cells-targeted immunogenicity increment, dendritic cells (DCs)-targeted vaccine delivery and T cells-mediated tumor elimination. Only limited immune efficacy could be achieved by strengthening the function of single type of cells. Therefore, building an effective immunotherapeutic nanoplatform by simultaneously modulating the functions of multiple cells involved in immune process is urgently demanded. However, it is challenging to modulate multiple cells since the on-demand delivery of diverse agents to different cells is restricted by inherent different target sites. Herein, as a proof of concept, dual tailor-made metal organic framework (MOF) nanoparticles based on zeolitic imidazolate framework-8 (ZIF-8) are designed to comprehensively enhance the immunotherapy via the spatiotemporal cooperation of various therapeutic agents including photothermal agent IR820, adjuvant imiquimod (R837) and immunomodulator 1-methyl-D-tryptophan (1 MT). On one hand, IR820@ZIF-8 is modified with hyaluronic acid for realizing tumor-targeted photothermal therapy, accompanied with the release of tumor antigens. On the other hand, (R837 +1 MT)@ZIF-8 is modified with mannan for achieving DCs-targeted immune amplification. The synergistic tumor cells-targeted treatment and DCs-targeted immunomodulation can efficiently overcome two major obstacles in immunotherapy: inadequate activation of immune response and immune evasion, offering powerful platform against invasive malignancy and rechallenged tumors.
机译：一种有效的抗肿瘤免疫应答依赖于包括肿瘤细胞靶向免疫原性增量，树突细胞（DC）的基于多细胞的方法，树突细胞（DC） - 介导的肿瘤消除。通过强化单一类型细胞的功能，才能实现有限的免疫效果。因此，通过同时调节有效的免疫治疗纳米纳薄形状，迫切需要迫切地调节涉及免疫过程中涉及的多个细胞的功能。然而，在调节多个细胞是挑战以来，由于对不同细胞的点播递送是由固有的不同目标位点限制。在此，作为概念证据，基于沸石咪唑酯框架-8（ZIF-8）的双量裁金属有机框架（MOF）纳米颗粒被设计成通过各种治疗剂的时空配合全面地增强免疫疗法，包括光热试剂IR820 ，佐剂咪唑（R837）和免疫调节剂1-甲基-D-色氨酸（1mT）。一方面，IR820 @ ZIF-8用透明质酸改性，用于实现肿瘤靶向的光热疗，伴随着肿瘤抗原的释放。另一方面，（R837 +1mt）@ ZIF-8用Mannan改性以实现DCS靶向免疫扩增。协同肿瘤细胞靶向治疗和DCS靶向免疫调节可以有效地克服免疫疗法的两个主要障碍：免疫反应激活和免疫逃避的激活，提供强大的侵袭性恶性肿瘤和重新激增的肿瘤平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号